Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 33,180 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Chemotherapy-Induced Nausea and Vomiting
Interventions: Palonosetron, Ondansetron, Placebo to Ondansetron, Placebo to Palonosetron; Drug
Lead sponsor: Helsinn Healthcare SA; Industry
Eligibility: Up to 16 Years
Enrollment: 502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 14
States / cities: Little Rock, Arkansas • Duarte, California • Aurora, Colorado + 11 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: erlotinib, sunitinib, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 18
States / cities: Birmingham, Alabama • Mobile, Alabama • Antioch, California + 13 more

Conditions: SCI - Spinal Cord Injury, Neuropathic Pain
Interventions: CBD/CBD-A, Placebo; Drug · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 64 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Fibromyalgia
Interventions: Duloxetine, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 15
States / cities: Birmingham, Alabama • Mesa, Arizona • Los Angeles, California + 12 more

Conditions: Persian Gulf Syndrome
Interventions: Carnosine, Placebo; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 34 Years to 82 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Type 2 Diabetes, Ketone Body Metabolism, Ketones, Metabolism
Interventions: Ketone Ester Acute, Placebo Acute; Dietary Supplement
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Jet Lag Disorder
Interventions: Tasimelteon, Placebo; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Alameda, California • Santa Monica, California • Chevy Chase, Maryland

Conditions: Healthy
Interventions: TG-0054; Drug
Lead sponsor: GPCR Therapeutics, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pruritis
Interventions: Sarna, Cetaphil; Drug
Lead sponsor: Wake Forest University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Rheumatoid Arthritis
Interventions: Abatacept (BMS-188667), Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2009
U.S. locations: 26
States / cities: Birmingham, Alabama • Huntsville, Alabama • Long Beach, California + 23 more

Conditions: Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer
Interventions: placebo, therapeutic conventional surgery, laboratory biomarker analysis, lycopene; Other · Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Traumatic Brain Injury
Interventions: Recombinant human Growth Hormone, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 50 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 3
States / cities: Bakersfield, California • Dallas, Texas

Conditions: Genital Herpes
Interventions: AG-707; Drug
Lead sponsor: Agenus Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 3
States / cities: Indianapolis, Indiana • Portland, Oregon • Seattle, Washington

Conditions: Congestive Heart Failure
Interventions: Irbesartan, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 60 Years and older
Enrollment: 4,128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 60
States / cities: Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 57 more

Conditions: Allergic Rhinitis
Interventions: BDP Nasal Aerosol, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 547 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 63
States / cities: Hot Springs, Arkansas • Costa Mesa, California • Downey, California + 50 more

Conditions: Obesity
Interventions: Acetazolamide; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 100 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Bipolar Depression
Interventions: Lumateperone, Placebo; Drug · Other
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 14
States / cities: Birmingham, Alabama • Sherman Oaks, California • Miami, Florida + 11 more

Conditions: Psychological Effects of Study Drug
Interventions: Lactose (inactive placebo), midomafetamine HCl; Drug
Lead sponsor: Resilient Pharmaceuticals; Industry
Eligibility: 21 Years and older
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2022
U.S. locations: 3
States / cities: Boulder, Colorado • Santa Fe, New Mexico • Mt. Pleasant, South Carolina

Conditions: Papilloma
Interventions: diindolylmethane (DIM), 585 nm pulsed dye laser; Dietary Supplement · Device
Lead sponsor: Boston University; Other
Eligibility: 10 Years to 21 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity, Hyperlipidemia, Hypertension
Interventions: Antioxidant diet, Antioxidant supplement, Placebo; Behavioral · Dietary Supplement
Lead sponsor: Christopher Gardner; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Stanford, California

Conditions: Methamphetamine Dependence
Interventions: Entacapone, Methamphetamine, Placebo; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Healthy Subjects
Interventions: ICP-332 Tablets, ICP-332 Placebo Tablets; Drug
Lead sponsor: InnoCare Pharma Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Alcohol Drinking
Interventions: 21mg transdermal nicotine patch (Nicoderm CQ), 1mg nicotine nasal spray, placebo nasal spray; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Bardet Biedl Syndrome (BBS), Alström Syndrome (AS)
Interventions: Setmelanotide, Placebo; Drug
Lead sponsor: Rhythm Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 6
States / cities: San Diego, California • Springfield, Massachusetts • New York, New York + 3 more

Search by objective public record fields.

Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients

A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone

Effects of CBD/CBD-A Oral Extract on Resting-state EEG and Neuropathic Pain Symptoms After SCI

Duloxetine Versus Placebo in the Treatment of FMS

Treatment Study of Carnosine Versus Placebo in Gulf War Illness (GWI)

Effects of Ketone Ester Consumption on Exercise Tolerance and Cardiac Function

A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder

Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of TG-0054 With Single IV Doses Escalation in Healthy Volunteers

Comparative Study of the Efficacy of SARNA Sensitive Lotion for Treatment of Uremic Itch in Adult Hemodialysis Patients

Abatacept With Methotrexate- Phase IIB

Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer

Recombinant Human Growth Hormone During Rehabilitation From Traumatic Brain Injury.

Trial Evaluating Safety, Tolerability and Immune Response of AG-707

Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)

Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR)

Carbonic Anhydrase Inhibitors and Carbonation: A Novel Approach to Reduce Soda Consumption

Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally

Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers

New Therapy of Laryngeal Papilloma In Children

Effects of Dietary Antioxidants on Cardiovascular Risk Factors

Pilot Study of Entacapone for Methamphetamine Abuse

Phase I Study of ICP-332 in Healthy Subjects

Do Treatments for Smoking Cessation Affect Alcohol Drinking? Study 1: Nicotine Replacement Therapy

Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity